ID   SPTB1_HUMAN             Reviewed;        2137 AA.
AC   P11277; Q15510; Q15519;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 5.
DT   28-JUN-2023, entry version 225.
DE   RecName: Full=Spectrin beta chain, erythrocytic;
DE   AltName: Full=Beta-I spectrin;
GN   Name=SPTB; Synonyms=SPTB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), AND VARIANTS ASN-439 AND
RP   ASP-1151.
RX   PubMed=2195026; DOI=10.1016/s0021-9258(19)38473-x;
RA   Winkelmann J.C., Chang J.G., Tse W.T., Scarpa A.L., Marchesi V.T.,
RA   Forget B.G.;
RT   "Full-length sequence of the cDNA for human erythroid beta-spectrin.";
RL   J. Biol. Chem. 265:11827-11832(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [3]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=2056132; DOI=10.1172/jci115307;
RA   Garbarz M., Tse W.T., Gallagher P.G., Picat C., Lecomte M.C., Galibert F.,
RA   Dhermy D., Forget B.G.;
RT   "Spectrin Rouen (beta 220-218), a novel shortened beta-chain variant in a
RT   kindred with hereditary elliptocytosis. Characterization of the molecular
RT   defect as exon skipping due to a splice site mutation.";
RL   J. Clin. Invest. 88:76-81(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1055-2137 (ISOFORM 2), AND VARIANT ASP-1151.
RC   TISSUE=Skeletal muscle;
RX   PubMed=2243099; DOI=10.1016/s0021-9258(17)30525-2;
RA   Winkelmann J.C., Costa F.F., Linzie B.L., Forget B.G.;
RT   "Beta spectrin in human skeletal muscle. Tissue-specific differential
RT   processing of 3' beta spectrin pre-mRNA generates a beta spectrin isoform
RT   with a unique carboxyl terminus.";
RL   J. Biol. Chem. 265:20449-20454(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2002-2137 (ISOFORM 1).
RX   PubMed=1840591; DOI=10.1016/s0021-9258(18)98598-4;
RA   Gallagher P.G., Tse W.T., Costa F., Scarpa A., Boivin P., Delaunay J.,
RA   Forget B.G.;
RT   "A splice site mutation of the beta-spectrin gene causing exon skipping in
RT   hereditary elliptocytosis associated with a truncated beta-spectrin
RT   chain.";
RL   J. Biol. Chem. 266:15154-15159(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 928-1756 (ISOFORMS 1/2/3), AND VARIANT
RP   ASP-1151.
RX   PubMed=1976574; DOI=10.1016/0378-1119(90)90104-y;
RA   Yoon S.H., Kentros C.G., Prchal J.T.;
RT   "Identification of an unusual deletion within homologous repeats of human
RT   reticulocyte beta-spectrin and probable peptide polymorphism.";
RL   Gene 91:297-302(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1334-1432 (ISOFORMS 1/2/3), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1909-2137 (ISOFORM 1), AND VARIANT ARG-1374.
RX   PubMed=3390609;
RA   Winkelmann J.C., Leto T.L., Watkins P.C., Eddy R., Shows T.B.,
RA   Linnenbach A.J., Sahr K.E., Kathuria N., Marchesi V.T., Forget B.G.;
RT   "Molecular cloning of the cDNA for human erythrocyte beta-spectrin.";
RL   Blood 72:328-334(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1209-1482 (ISOFORMS 1/2/3).
RX   PubMed=3478706; DOI=10.1073/pnas.84.21.7468;
RA   Prchal J.T., Morley B.J., Yoon S.-H., Coetzer T.L., Palek J., Conboy J.G.,
RA   Kan Y.W.;
RT   "Isolation and characterization of cDNA clones for human erythrocyte beta-
RT   spectrin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7468-7472(1987).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-18.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [10]
RP   DOMAINS.
RX   PubMed=6472478; DOI=10.1038/311177a0;
RA   Speicher D.W., Marchesi V.T.;
RT   "Erythrocyte spectrin is comprised of many homologous triple helical
RT   segments.";
RL   Nature 311:177-180(1984).
RN   [11]
RP   PHOSPHORYLATION AT THR-2110; SER-2114; SER-2117; SER-2123; SER-2125 AND
RP   SER-2128.
RX   PubMed=15065869; DOI=10.1021/bi036092x;
RA   Tang H.Y., Speicher D.W.;
RT   "In vivo phosphorylation of human erythrocyte spectrin occurs in a
RT   sequential manner.";
RL   Biochemistry 43:4251-4262(2004).
RN   [12]
RP   INVOLVEMENT IN SPH2.
RX   PubMed=19538529; DOI=10.1111/j.1365-2141.2009.07759.x;
RA   Maciag M., Plochocka D., Adamowicz-Salach A., Burzynska B.;
RT   "Novel beta-spectrin mutations in hereditary spherocytosis associated with
RT   decreased levels of mRNA.";
RL   Br. J. Haematol. 146:326-332(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-104; THR-2073; SER-2123 AND
RP   SER-2125, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2043, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION).
RX   PubMed=29459732; DOI=10.1038/s41564-018-0111-0;
RA   Thomas J.A., Tan M.S.Y., Bisson C., Borg A., Umrekar T.R., Hackett F.,
RA   Hale V.L., Vizcay-Barrena G., Fleck R.A., Snijders A.P., Saibil H.R.,
RA   Blackman M.J.;
RT   "A protease cascade regulates release of the human malaria parasite
RT   Plasmodium falciparum from host red blood cells.";
RL   Nat. Microbiol. 3:447-455(2018).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1064-1275.
RX   PubMed=15062087; DOI=10.1016/j.str.2004.02.022;
RA   Kusunoki H., MacDonald R.I., Mondragon A.;
RT   "Structural insights into the stability and flexibility of unusual
RT   erythroid spectrin repeats.";
RL   Structure 12:645-656(2004).
RN   [18]
RP   REVIEW ON VARIANTS.
RX   PubMed=8844207;
RX   DOI=10.1002/(sici)1098-1004(1996)8:2<97::aid-humu1>3.0.co;2-m;
RA   Maillet P., Alloisio N., Morle L., Delaunay J.;
RT   "Spectrin mutations in hereditary elliptocytosis and hereditary
RT   spherocytosis.";
RL   Hum. Mutat. 8:97-107(1996).
RN   [19]
RP   VARIANT EL3 CAGLIARI GLY-2018.
RX   PubMed=8226774; DOI=10.1016/s0021-9258(18)41578-5;
RA   Sahr K.E., Coetzer T.L., Moy L.S., Derick L.H., Chishti A.H., Jarolim P.,
RA   Lorenzo F., del Giudice E.M., Iolascon A., Gallanello R., Cao A.,
RA   Delaunay J., Liu S.-C., Palek J.;
RT   "Spectrin Cagliari: an Ala-->Gly substitution in helix 1 of beta spectrin
RT   repeat 17 that severely disrupts the structure and self-association of the
RT   erythrocyte spectrin heterodimer.";
RL   J. Biol. Chem. 268:22656-22662(1993).
RN   [20]
RP   INVOLVEMENT IN SPH2, AND VARIANT SPH2 ARG-202.
RX   PubMed=8102379; DOI=10.1172/jci116628;
RA   Becker P.S., Tse W.T., Lux S.E., Forget B.G.;
RT   "Beta spectrin Kissimmee: a spectrin variant associated with autosomal
RT   dominant hereditary spherocytosis and defective binding to protein 4.1.";
RL   J. Clin. Invest. 92:612-616(1993).
RN   [21]
RP   VARIANT EL3 PROVIDENCE PRO-2019.
RX   PubMed=7883966; DOI=10.1172/jci117766;
RA   Gallagher P.G., Weed S.A., Tse W.T., Benoit L., Morrow J.S., Marchesi S.L.,
RA   Mohandas N., Forget B.G.;
RT   "Recurrent fatal hydrops fetalis associated with a nucleotide substitution
RT   in the erythrocyte beta-spectrin gene.";
RL   J. Clin. Invest. 95:1174-1182(1995).
RN   [22]
RP   VARIANTS EL3 VAL-2023 AND ARG-2024.
RX   PubMed=8018926;
RA   Parquet N., Devaux I., Boulanger L., Galand C., Boivin P., Lecomte M.-C.,
RA   Dhermy D., Garbarz M.;
RT   "Identification of three novel spectrin alpha I/74 mutations in hereditary
RT   elliptocytosis: further support for a triple-stranded folding unit model of
RT   the spectrin heterodimer contact site.";
RL   Blood 84:303-308(1994).
RN   [23]
RP   VARIANT EL3 PRO-2053.
RX   PubMed=1975598; DOI=10.1172/jci114792;
RA   Tse W.T., Lecomte M.-C., Costa F.F., Garbarz M., Feo C., Boivin P.,
RA   Dhermy D., Forget B.G.;
RT   "Point mutation in the beta-spectrin gene associated with alpha I/74
RT   hereditary elliptocytosis. Implications for the mechanism of spectrin dimer
RT   self-association.";
RL   J. Clin. Invest. 86:909-916(1990).
CC   -!- FUNCTION: Spectrin is the major constituent of the cytoskeletal network
CC       underlying the erythrocyte plasma membrane. It associates with band 4.1
CC       and actin to form the cytoskeletal superstructure of the erythrocyte
CC       plasma membrane.
CC   -!- SUBUNIT: Composed of nonhomologous chains, alpha and beta, which
CC       aggregate to form dimers, tetramers, and higher polymers.
CC   -!- INTERACTION:
CC       P11277; P05067: APP; NbExp=6; IntAct=EBI-514908, EBI-77613;
CC       P11277; O95295: SNAPIN; NbExp=3; IntAct=EBI-514908, EBI-296723;
CC       P11277; P02549: SPTA1; NbExp=4; IntAct=EBI-514908, EBI-375617;
CC       P11277; P50463: Csrp3; Xeno; NbExp=6; IntAct=EBI-514908, EBI-12502290;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Cytoplasm, cell cortex.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P11277-1; Sequence=Displayed;
CC       Name=2; Synonyms=Muscle-specific;
CC         IsoId=P11277-2; Sequence=VSP_000719;
CC       Name=3;
CC         IsoId=P11277-3; Sequence=VSP_007242;
CC   -!- PTM: The first phosphorylation event occurs on Ser-2114, followed by
CC       Ser-2125, Ser-2123, Ser-2128, Ser-2117, and Thr-2110.
CC       {ECO:0000269|PubMed:15065869}.
CC   -!- PTM: (Microbial infection) Probably cleaved by P.falciparum SERA6; the
CC       cleavage results in SPTB solubilization causing the disruption of the
CC       actin cytoskeleton and the rupture of the erythrocyte cell membrane
CC       releasing the merozoites. {ECO:0000269|PubMed:29459732}.
CC   -!- DISEASE: Elliptocytosis 3 (EL3) [MIM:617948]: A Rhesus-unlinked form of
CC       hereditary elliptocytosis, a genetically heterogeneous hematologic
CC       disorder characterized by variable hemolytic anemia and elliptical or
CC       oval red cell shape. Inheritance can be autosomal dominant or autosomal
CC       recessive. {ECO:0000269|PubMed:1975598, ECO:0000269|PubMed:7883966,
CC       ECO:0000269|PubMed:8018926, ECO:0000269|PubMed:8226774}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Spherocytosis 2 (SPH2) [MIM:616649]: An autosomal dominant
CC       form of hereditary spherocytosis, a group of hematologic disorders
CC       characterized by numerous abnormally shaped erythrocytes which are
CC       generally spheroidal. Clinical manifestations include chronic hemolytic
CC       anemia, jaundice, and splenomegaly, with variable severity.
CC       {ECO:0000269|PubMed:19538529, ECO:0000269|PubMed:8102379}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: This complex is anchored to the cytoplasmic face of the
CC       plasma membrane via another protein, ankyrin, which binds to beta-
CC       spectrin and mediates the binding of the whole complex to a
CC       transmembrane protein band 3. The interaction of erythrocyte spectrin
CC       with other proteins through specific binding domains lead to the
CC       formation of an extensive subplasmalemmal meshwork which is thought to
CC       be responsible for the maintenance of the biconcave shape of human
CC       erythrocytes, for the regulation of plasma membrane components and for
CC       the maintenance of the lipid asymmetry of the plasma membrane.
CC   -!- MISCELLANEOUS: [Isoform 3]: Due to exon skipping. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the spectrin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J05500; AAA60578.1; -; mRNA.
DR   EMBL; J05500; AAA60579.1; -; mRNA.
DR   EMBL; AL121774; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M37884; AAA63259.1; -; mRNA.
DR   EMBL; M37885; AAA60571.1; -; mRNA.
DR   EMBL; M57948; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X59510; CAA42097.1; -; mRNA.
DR   EMBL; X59511; CAA42098.1; -; mRNA.
DR   EMBL; M18054; AAA60572.1; -; mRNA.
DR   CCDS; CCDS32099.1; -. [P11277-2]
DR   CCDS; CCDS32100.1; -. [P11277-1]
DR   PIR; A37064; SJHUB.
DR   RefSeq; NP_000338.3; NM_000347.5.
DR   RefSeq; NP_001020029.1; NM_001024858.2. [P11277-2]
DR   RefSeq; XP_005268080.1; XM_005268023.4.
DR   RefSeq; XP_016877101.1; XM_017021612.1. [P11277-2]
DR   RefSeq; XP_016877103.1; XM_017021614.1.
DR   PDB; 1S35; X-ray; 2.40 A; A=1063-1275.
DR   PDB; 3EDU; X-ray; 2.10 A; A=1692-1907.
DR   PDB; 3F57; X-ray; 2.90 A; A/B=1686-1907.
DR   PDB; 3KBT; X-ray; 2.75 A; A/B=1583-1906.
DR   PDB; 3KBU; X-ray; 2.75 A; A/B=1583-1906.
DR   PDB; 3LBX; X-ray; 2.80 A; B=1902-2084.
DR   PDBsum; 1S35; -.
DR   PDBsum; 3EDU; -.
DR   PDBsum; 3F57; -.
DR   PDBsum; 3KBT; -.
DR   PDBsum; 3KBU; -.
DR   PDBsum; 3LBX; -.
DR   AlphaFoldDB; P11277; -.
DR   SMR; P11277; -.
DR   BioGRID; 112588; 91.
DR   DIP; DIP-1021N; -.
DR   IntAct; P11277; 24.
DR   STRING; 9606.ENSP00000451752; -.
DR   CarbonylDB; P11277; -.
DR   GlyConnect; 2860; 1 O-GlcNAc glycan (5 sites).
DR   GlyCosmos; P11277; 5 sites, 1 glycan.
DR   GlyGen; P11277; 6 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; P11277; -.
DR   MetOSite; P11277; -.
DR   PhosphoSitePlus; P11277; -.
DR   BioMuta; SPTB; -.
DR   DMDM; 215274269; -.
DR   SWISS-2DPAGE; P11277; -.
DR   EPD; P11277; -.
DR   jPOST; P11277; -.
DR   MassIVE; P11277; -.
DR   MaxQB; P11277; -.
DR   PaxDb; P11277; -.
DR   PeptideAtlas; P11277; -.
DR   ProteomicsDB; 52731; -. [P11277-1]
DR   ProteomicsDB; 52732; -. [P11277-2]
DR   ProteomicsDB; 52733; -. [P11277-3]
DR   ABCD; P11277; 1 sequenced antibody.
DR   Antibodypedia; 183; 123 antibodies from 22 providers.
DR   DNASU; 6710; -.
DR   Ensembl; ENST00000389720.4; ENSP00000374370.4; ENSG00000070182.21. [P11277-1]
DR   Ensembl; ENST00000389722.7; ENSP00000374372.3; ENSG00000070182.21. [P11277-2]
DR   Ensembl; ENST00000644917.1; ENSP00000495909.1; ENSG00000070182.21. [P11277-2]
DR   GeneID; 6710; -.
DR   KEGG; hsa:6710; -.
DR   MANE-Select; ENST00000644917.1; ENSP00000495909.1; NM_001355436.2; NP_001342365.1. [P11277-2]
DR   UCSC; uc001xhr.4; human. [P11277-1]
DR   AGR; HGNC:11274; -.
DR   CTD; 6710; -.
DR   DisGeNET; 6710; -.
DR   GeneCards; SPTB; -.
DR   HGNC; HGNC:11274; SPTB.
DR   HPA; ENSG00000070182; Tissue enhanced (bone marrow, skeletal muscle, tongue).
DR   MalaCards; SPTB; -.
DR   MIM; 182870; gene.
DR   MIM; 616649; phenotype.
DR   MIM; 617948; phenotype.
DR   neXtProt; NX_P11277; -.
DR   OpenTargets; ENSG00000070182; -.
DR   Orphanet; 288; Hereditary elliptocytosis.
DR   Orphanet; 822; Hereditary spherocytosis.
DR   PharmGKB; PA36103; -.
DR   VEuPathDB; HostDB:ENSG00000070182; -.
DR   eggNOG; KOG0517; Eukaryota.
DR   GeneTree; ENSGT00940000158908; -.
DR   HOGENOM; CLU_000146_1_2_1; -.
DR   InParanoid; P11277; -.
DR   OMA; EPADMTS; -.
DR   OrthoDB; 2872403at2759; -.
DR   PhylomeDB; P11277; -.
DR   TreeFam; TF313446; -.
DR   PathwayCommons; P11277; -.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6807878; COPI-mediated anterograde transport.
DR   SignaLink; P11277; -.
DR   SIGNOR; P11277; -.
DR   BioGRID-ORCS; 6710; 16 hits in 1153 CRISPR screens.
DR   ChiTaRS; SPTB; human.
DR   EvolutionaryTrace; P11277; -.
DR   GeneWiki; SPTB; -.
DR   GenomeRNAi; 6710; -.
DR   Pharos; P11277; Tbio.
DR   PRO; PR:P11277; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P11277; protein.
DR   Bgee; ENSG00000070182; Expressed in gastrocnemius and 152 other tissues.
DR   ExpressionAtlas; P11277; baseline and differential.
DR   Genevisible; P11277; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:BHF-UCL.
DR   GO; GO:0030054; C:cell junction; IBA:GO_Central.
DR   GO; GO:0042995; C:cell projection; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0030864; C:cortical actin cytoskeleton; IBA:GO_Central.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0098794; C:postsynapse; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0008091; C:spectrin; TAS:ProtInc.
DR   GO; GO:0014731; C:spectrin-associated cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0003779; F:actin binding; TAS:ProtInc.
DR   GO; GO:0051015; F:actin filament binding; IDA:UniProtKB.
DR   GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; IEA:InterPro.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0051693; P:actin filament capping; IEA:UniProtKB-KW.
DR   GO; GO:0098885; P:modification of postsynaptic actin cytoskeleton; IDA:SynGO.
DR   CDD; cd21319; CH_SPTB_rpt2; 1.
DR   CDD; cd21317; CH_SPTBN2_rpt1; 1.
DR   CDD; cd00176; SPEC; 8.
DR   Gene3D; 1.20.58.60; -; 12.
DR   Gene3D; 1.10.418.10; Calponin-like domain; 2.
DR   InterPro; IPR001589; Actinin_actin-bd_CS.
DR   InterPro; IPR001715; CH_dom.
DR   InterPro; IPR036872; CH_dom_sf.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR016343; Spectrin_bsu.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   PANTHER; PTHR11915:SF248; SPECTRIN BETA CHAIN, ERYTHROCYTIC; 1.
DR   PANTHER; PTHR11915; SPECTRIN/FILAMIN RELATED CYTOSKELETAL PROTEIN; 1.
DR   Pfam; PF00307; CH; 2.
DR   Pfam; PF00435; Spectrin; 17.
DR   PIRSF; PIRSF002297; Spectrin_beta_subunit; 1.
DR   SMART; SM00033; CH; 2.
DR   SMART; SM00150; SPEC; 17.
DR   SUPFAM; SSF47576; Calponin-homology domain, CH-domain; 1.
DR   SUPFAM; SSF46966; Spectrin repeat; 13.
DR   PROSITE; PS00019; ACTININ_1; 1.
DR   PROSITE; PS00020; ACTININ_2; 1.
DR   PROSITE; PS50021; CH; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Actin capping; Actin-binding; Alternative splicing;
KW   Cytoplasm; Cytoskeleton; Direct protein sequencing; Disease variant;
KW   Elliptocytosis; Hereditary hemolytic anemia; Phosphoprotein;
KW   Reference proteome; Repeat.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT   CHAIN           2..2137
FT                   /note="Spectrin beta chain, erythrocytic"
FT                   /id="PRO_0000073459"
FT   DOMAIN          54..158
FT                   /note="Calponin-homology (CH) 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   DOMAIN          173..278
FT                   /note="Calponin-homology (CH) 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   REPEAT          303..411
FT                   /note="Spectrin 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          423..525
FT                   /note="Spectrin 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          529..635
FT                   /note="Spectrin 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          638..741
FT                   /note="Spectrin 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          744..846
FT                   /note="Spectrin 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          851..950
FT                   /note="Spectrin 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          956..1058
FT                   /note="Spectrin 7"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1062..1165
FT                   /note="Spectrin 8"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1170..1257
FT                   /note="Spectrin 9"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1275..1375
FT                   /note="Spectrin 10"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1389..1465
FT                   /note="Spectrin 11"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1481..1582
FT                   /note="Spectrin 12"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1585..1688
FT                   /note="Spectrin 13"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1690..1793
FT                   /note="Spectrin 14"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1797..1899
FT                   /note="Spectrin 15"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1906..2006
FT                   /note="Spectrin 16"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2013..2075
FT                   /note="Spectrin 17"
FT                   /evidence="ECO:0000255"
FT   REGION          1..30
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..275
FT                   /note="Actin-binding"
FT   REGION          2074..2117
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..16
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2074..2091
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            165..166
FT                   /note="(Microbial infection) Cleavage; by P.falciparum
FT                   SERA6"
FT                   /evidence="ECO:0000269|PubMed:29459732"
FT   SITE            167..168
FT                   /note="(Microbial infection) Cleavage; by P.falciparum
FT                   SERA6"
FT                   /evidence="ECO:0000269|PubMed:29459732"
FT   MOD_RES         36
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P15508"
FT   MOD_RES         104
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P15508"
FT   MOD_RES         2043
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         2073
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2110
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15065869"
FT   MOD_RES         2114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15065869"
FT   MOD_RES         2117
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15065869"
FT   MOD_RES         2123
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15065869,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2125
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15065869,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15065869"
FT   VAR_SEQ         2074..2137
FT                   /note="LELKERQIAERPAEETGPQEEEGETAGEAPVSHHAATERTSPVSLWSRLSSS
FT                   WESLQPEPSHPY -> ASRGGRRDSRGGSSFPPCGHRENVPGQSLVSFV (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:2195026"
FT                   /id="VSP_007242"
FT   VAR_SEQ         2116..2137
FT                   /note="VSLWSRLSSSWESLQPEPSHPY -> GEEEGTWPQNLQQPPPPGQHKDGQKS
FT                   TGDERPTTEPLFKVLDTPLSEGDEPATLPAPRDHGQSVQMEGYLGRKHDLEGPNKKASN
FT                   RSWNNLYCVLRNSELTFYKDAKNLALGMPYHGEEPLALRHAICEIAANYKKKKHVFKLR
FT                   LSNGSEWLFHGKDEEEMLSWLQGVSTAINESQSIRVKAQSLPLPSLSGPDASLGKKDKE
FT                   KRFSFFPKKK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2243099"
FT                   /id="VSP_000719"
FT   VARIANT         202
FT                   /note="W -> R (in SPH2; spectrin Kissimmee;
FT                   dbSNP:rs121918646)"
FT                   /evidence="ECO:0000269|PubMed:8102379"
FT                   /id="VAR_001352"
FT   VARIANT         439
FT                   /note="S -> N (in dbSNP:rs229587)"
FT                   /evidence="ECO:0000269|PubMed:2195026"
FT                   /id="VAR_001353"
FT   VARIANT         525
FT                   /note="E -> K (in dbSNP:rs55752508)"
FT                   /id="VAR_061084"
FT   VARIANT         613
FT                   /note="S -> I (in dbSNP:rs3742601)"
FT                   /id="VAR_038514"
FT   VARIANT         1151
FT                   /note="N -> D (in dbSNP:rs77806)"
FT                   /evidence="ECO:0000269|PubMed:1976574,
FT                   ECO:0000269|PubMed:2195026, ECO:0000269|PubMed:2243099"
FT                   /id="VAR_001354"
FT   VARIANT         1374
FT                   /note="H -> R (in dbSNP:rs10132778)"
FT                   /evidence="ECO:0000269|PubMed:3390609"
FT                   /id="VAR_001355"
FT   VARIANT         1403
FT                   /note="R -> Q (in dbSNP:rs17180350)"
FT                   /id="VAR_001356"
FT   VARIANT         1408
FT                   /note="G -> R (in dbSNP:rs17245552)"
FT                   /id="VAR_038515"
FT   VARIANT         2018
FT                   /note="A -> G (in EL3; Cagliary; dbSNP:rs121918647)"
FT                   /evidence="ECO:0000269|PubMed:8226774"
FT                   /id="VAR_001357"
FT   VARIANT         2019
FT                   /note="S -> P (in EL3; Providence; dbSNP:rs121918648)"
FT                   /evidence="ECO:0000269|PubMed:7883966"
FT                   /id="VAR_001358"
FT   VARIANT         2023
FT                   /note="A -> V (in EL3; Paris; dbSNP:rs367841692)"
FT                   /evidence="ECO:0000269|PubMed:8018926"
FT                   /id="VAR_001359"
FT   VARIANT         2024
FT                   /note="W -> R (in EL3; Linguere; dbSNP:rs1225539653)"
FT                   /evidence="ECO:0000269|PubMed:8018926"
FT                   /id="VAR_001360"
FT   VARIANT         2025
FT                   /note="L -> R (in EL3; Buffalo; dbSNP:rs121918649)"
FT                   /id="VAR_001361"
FT   VARIANT         2053
FT                   /note="A -> P (in EL3; Kayes; dbSNP:rs121918645)"
FT                   /evidence="ECO:0000269|PubMed:1975598"
FT                   /id="VAR_001362"
FT   CONFLICT        403
FT                   /note="E -> G (in Ref. 1; AAA60578/AAA60579)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        612
FT                   /note="I -> M (in Ref. 1; AAA60578/AAA60579)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        629..631
FT                   /note="RKA -> ART (in Ref. 1; AAA60578/AAA60579)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        958..959
FT                   /note="NY -> TL (in Ref. 1; AAA60578/AAA60579)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1031
FT                   /note="D -> N (in Ref. 1; AAA60578/AAA60579)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1844..1845
FT                   /note="EL -> DV (in Ref. 1; AAA60578/AAA60579 and 3;
FT                   AAA63259)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1065..1085
FT                   /evidence="ECO:0007829|PDB:1S35"
FT   HELIX           1093..1128
FT                   /evidence="ECO:0007829|PDB:1S35"
FT   HELIX           1134..1192
FT                   /evidence="ECO:0007829|PDB:1S35"
FT   HELIX           1200..1236
FT                   /evidence="ECO:0007829|PDB:1S35"
FT   HELIX           1242..1271
FT                   /evidence="ECO:0007829|PDB:1S35"
FT   HELIX           1586..1605
FT                   /evidence="ECO:0007829|PDB:3KBT"
FT   HELIX           1616..1652
FT                   /evidence="ECO:0007829|PDB:3KBT"
FT   HELIX           1692..1713
FT                   /evidence="ECO:0007829|PDB:3EDU"
FT   HELIX           1722..1759
FT                   /evidence="ECO:0007829|PDB:3EDU"
FT   HELIX           1765..1818
FT                   /evidence="ECO:0007829|PDB:3EDU"
FT   HELIX           1838..1863
FT                   /evidence="ECO:0007829|PDB:3EDU"
FT   HELIX           1868..1891
FT                   /evidence="ECO:0007829|PDB:3EDU"
FT   HELIX           1902..1928
FT                   /evidence="ECO:0007829|PDB:3LBX"
FT   STRAND          1936..1938
FT                   /evidence="ECO:0007829|PDB:3LBX"
FT   HELIX           1941..1971
FT                   /evidence="ECO:0007829|PDB:3LBX"
FT   HELIX           1977..2033
FT                   /evidence="ECO:0007829|PDB:3LBX"
FT   HELIX           2041..2060
FT                   /evidence="ECO:0007829|PDB:3LBX"
FT   HELIX           2062..2069
FT                   /evidence="ECO:0007829|PDB:3LBX"
FT   HELIX           2073..2082
FT                   /evidence="ECO:0007829|PDB:3LBX"
SQ   SEQUENCE   2137 AA;  246468 MW;  311AE5CD53237610 CRC64;
     MTSATEFENV GNQPPYSRIN ARWDAPDDEL DNDNSSARLF ERSRIKALAD EREVVQKKTF
     TKWVNSHLAR VSCRITDLYK DLRDGRMLIK LLEVLSGEML PKPTKGKMRI HCLENVDKAL
     QFLKEQRVHL ENMGSHDIVD GNHRLVLGLI WTIILRFQIQ DIVVQTQEGR ETRSAKDALL
     LWCQMKTAGY PHVNVTNFTS SWKDGLAFNA LIHKHRPDLI DFDKLKDSNA RHNLEHAFNV
     AERQLGIIPL LDPEDVFTEN PDEKSIITYV VAFYHYFSKM KVLAVEGKRV GKVIDHAIET
     EKMIEKYSGL ASDLLTWIEQ TITVLNSRKF ANSLTGVQQQ LQAFSTYRTV EKPPKFQEKG
     NLEVLLFTIQ SRMRANNQKV YTPHDGKLVS DINRAWESLE EAEYRRELAL RNELIRQEKL
     EQLARRFDRK AAMRETWLSE NQRLVAQDNF GYDLAAVEAA KKKHEAIETD TAAYEERVRA
     LEDLAQELEK ENYHDQKRIT ARKDNILRLW SYLQELLQSR RQRLETTLAL QKLFQDMLHS
     IDWMDEIKAH LLSAEFGKHL LEVEDLLQKH KLMEADIAIQ GDKVKAITAA TLKFTEGKGY
     QPCDPQVIQD RISHLEQCFE ELSNMAAGRK AQLEQSKRLW KFFWEMDEAE SWIKEKEQIY
     SSLDYGKDLT SVLILQRKHK AFEDELRGLD AHLEQIFQEA HGMVARKQFG HPQIEARIKE
     VSAQWDQLKD LAAFCKKNLQ DAENFFQFQG DADDLKAWLQ DAHRLLSGED VGQDEGATRA
     LGKKHKDFLE ELEESRGVME HLEQQAQGFP EEFRDSPDVT HRLQALRELY QQVVAQADLR
     QQRLQEALDL YTVFGETDAC ELWMGEKEKW LAEMEMPDTL EDLEVVQHRF DILDQEMKTL
     MTQIDGVNLA ANSLVESGHP RSREVKQYQD HLNTRWQAFQ TLVSERREAV DSALRVHNYC
     VDCEETSKWI TDKTKVVEST KDLGRDLAGI IAIQRKLSGL ERDVAAIQAR VDALERESQQ
     LMDSHPEQKE DIGQRQKHLE ELWQGLQQSL QGQEDLLGEV SQLQAFLQDL DDFQAWLSIT
     QKAVASEDMP ESLPEAEQLL QQHAGIKDEI DGHQDSYQRV KESGEKVIQG QTDPEYLLLG
     QRLEGLDTGW NALGRMWESR SHTLAQCLGF QEFQKDAKQA EAILSNQEYT LAHLEPPDSL
     EAAEAGIRKF EDFLGSMENN RDKVLSPVDS GNKLVAEGNL YSDKIKEKVQ LIEDRHRKNN
     EKAQEASVLL RDNLELQNFL QNCQELTLWI NDKLLTSQDV SYDEARNLHN KWLKHQAFVA
     ELASHEGWLE NIDAEGKQLM DEKPQFTALV SQKLEALHRL WDELQATTKE KTQHLSAARS
     SDLRLQTHAD LNKWISAMED QLRSDDPGKD LTSVNRMLAK LKRVEDQVNV RKEELGELFA
     QVPSMGEEGG DADLSIEKRF LDLLEPLGRR KKQLESSRAK LQISRDLEDE TLWVEERLPL
     AQSADYGTNL QTVQLFMKKN QTLQNEILGH TPRVEDVLQR GQQLVEAAEI DCQDLEERLG
     HLQSSWDRLR EAAAGRLQRL RDANEAQQYY LDADEAEAWI GEQELYVISD EIPKDEEGAI
     VMLKRHLRQQ RAVEDYGRNI KQLASRAQGL LSAGHPEGEQ IIRLQGQVDK HYAGLKDVAE
     ERKRKLENMY HLFQLKRETD DLEQWISEKE LVASSPEMGQ DFDHVTLLRD KFRDFARETG
     AIGQERVDNV NAFIERLIDA GHSEAATIAE WKDGLNEMWA DLLELIDTRM QLLAASYDLH
     RYFYTGAEIL GLIDEKHREL PEDVGLDAST AESFHRVHTA FERELHLLGV QVQQFQDVAT
     RLQTAYAGEK AEAIQNKEQE VSAAWQALLD ACAGRRTQLV DTADKFRFFS MARDLLSWME
     SIIRQIETQE RPRDVSSVEL LMKYHQGINA EIETRSKNFS ACLELGESLL QRQHQASEEI
     REKLQQVMSR RKEMNEKWEA RWERLRMLLE VCQFSRDASV AEAWLIAQEP YLASGDFGHT
     VDSVEKLIKR HEAFEKSTAS WAERFAALEK PTTLELKERQ IAERPAEETG PQEEEGETAG
     EAPVSHHAAT ERTSPVSLWS RLSSSWESLQ PEPSHPY
//
